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Summary FCE 23762 is a new doxorubicin derivative obtained by appending a methoxymorpholinyl group at
position 3' of the sugar moiety. The compound is >80 times more potent than doxorubicin, it is highly
lipophilic, and presents equivalent anti-tumour activity when administered by i.p., i.v. or oral route.
The pattern of anti-tumour activity of FCE 23762 differs from that of doxorubicin in maintaining
anti-tumour activity against two P388 murine leukaemia sublines resistant to doxorubicin and, although at
borderline levels of efficacy, against LoVo human colon adenocarcinoma resistant to doxorubicin.
FCE 23762 exhibits remarkable efficacy against MX-1 human mammary carcinoma, with most treated mice
being cured both after i.v. and oral treatment. Anti-tumour activity was also observed against L1210 murine
leukaemia and two sublines resistant to cis-platinum and melphalan, M5076 murine reticulosarcoma, MTV
murine mammary carcinoma and N592 human small cell lung cancer.
A major obstacle to successful chemotherapy with many
cancer chemotherapeutics and particularly with anthracyclines,
vinca alkaloid, anthracenediones and epipodophyllotoxins is
the emergence of multidrug resistance (MDR) observed in
experimental conditions as well as in patients (Goldstein et
al., 1989; Rothenberger & Ling, 1989). This phenomenon has
prompted extensive efforts to search for chemotherapeutic
treatments active on MDR tumours.
Tumour cells presenting the MDR phenotype (Kaye, 1988;
Beck, 1987) are resistant to several classes of drugs because
of the presence of high levels of pl70 (Endicott et al., 1989),
a membrane glycoprotein able to recognise and extrude the
cross-resistant compounds before cytotoxic intracellular con-
centrations can be reached.
The two most explored approaches for overcoming MDR
are the combination of p170-inhibitors (the so-called resis-
tance modulators) with cross-resistant drugs (Beck, 1990), or
the synthesis of new analogues not extruded by p170 (Odaini
et al., 1986; Watanabe et al., 1988; Coley et al., 1990; Grandi
et al., 1990a,b). In both cases, activity on MDR cells is
obtained because drugs have been made able to reach cyto-
toxic intracellular levels. Anthracyclines are an important
class of clinically effective anti-tumour drugs, and much
effort has been devoted to collecting structure-activity data
in relation to their effect on MDR cells (Grandi et al.,
1990b).
Thus, several derivatives of doxorubicin (DX) or dauno-
rubicin have been synthesised and found to be equally effec-
tive in vitro on sensitive and MDR cells. Among these, one of
the most promising appears to be the class of morpholino
anthracyclines, which were found to possess high effective-
ness in vivo, as well as in vitro, on DX-resistant tumours
(Watanabe et al., 1988; Grandi et al., 1990b).
In this paper, we report the pattern of anti-tumour activity
of FCE 23762 on a panel of murine leukaemias and murine
and human solid tumours.
FCE 23762 is a new DX derivative bearing a methoxy
morpholinyl group at position 3' of the sugar moiety. Prelim-
inary results on its cytotoxic activity, intracellular accumula-
tion on LoVo and LoVo/DX human colon adenocarcinoma
cells and anti-tumour activity have already been presented
(Grandi et al., 1990b). FCE 23762 is not cross-resistant on
MDR cells, and maintains effectiveness on CEM/VM-1 cells,
a human leukaemia cell line with the atypical-MDR pheno-
type (Grandi et al., 1990a).
Materials and methods
Drug preparation
FCE 23762 was synthesised in the laboratories of Farmitalia
C.Erba (Milan, Italy) (Figure 1), FCE 23762 and DX were
dissolved in distilled water and the concentrations were
checked spectrophotometrically (FCE 23762, A,max = 495
(CH30H), El% = 173; DX).
Melphalan (L-PAM) (Sigma Chemical Co., St Louis, IL,
USA) was weighed and dissolved in 1 N HCI (20 mg ml-'),
and further dissolved in H20; cis-platinum (cDDP) (Farmi-
talia C.Erba, Milan, Italy) was weighed and dissolved in
water; 1,3 bis (2-chloroethyl)-l-nitrosourea (BCNU; Simes
SpA, Vicenza, Italy) was weighed and dissolved in ethanol
and H20.
Animals
Inbred DBA/2, C57B1/6, C3H/He, first generation hybrid
C57B1/6 x DBA/2F1 (BD2F1) and BALB/c x DBA/2F1
(CD2F1) adult mice of both sexes were used to evaluate the
anti-tumour activity.
In experiments with human tumour xenografts, adult
female Swiss/nu/nu mice were employed. All animals were
supplied by Charles River (Calco, Como, Italy). The conven-
tional mice were 2-3-months old, weighed 20-22 g and were
kept under standard laboratory conditions. Nude mice were
Figure 1 Structure of FCE 23762.
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4-6 weeks old, weighed 20-25 g and were maintained in
cages with paper filter covers; food and bedding were steri-
lised and water was acidified (pH 2.5-3). Animal health was
monitored every 4-6 weeks by serological testing: the
animals were free of infectious pathogens, including Mouse
hepatitis Virus, Sendai virus and mycoplasma pulmonis.
Tumours
Leukaemias The P388 murine leukaemia was maintained by
weekly i.p. passages of 106 cells in DBA/2 mice, according to
Geran et al. (1972). For experiments, 106 cells/mouse i.p. or
i.v. and 104 cells/mouse i.c. were transplanted in CD2F1
mice.
Two different P388 sublines resistant to DX were used.
The first, P388/DX Johnson subline (Johnson et al., 1978),
was maintained by weekly i.p. passages of 106 cells in BD2Fl
mice and in experiments 105 cells i.v. and 106 cells sub-
cutaneously and i.p. were transplanted in the same strain of
mice.
The second one, the P388 DX Schabel subline, was obtain-
ed by repeated exposure to the drug in Dr F. Schabel's
laboratory (Southern Research Institute, Birmingham, AL,
USA) and maintained in our facilities in BD2F1 mice, given
weekly i.p. passages of 107 cells/mouse. The animals were
treated 48 h after tumour transplantation with 6 mg kg-' of
DX. For experimental studies 106 cells/mouse i.p. or i.v. were
transplanted. The L1210 murine leukaemia and its subline
resistant to L-PAM, L1210/L-PAM (originally obtained from
the NCI, NIH, Bethesda, MD, USA) were maintained by
weekly i.p. passages of 106 cells in DBA/2 mice; in the case of
L1210/L-PAM, mice were treated weekly with 7.5 mg kg-'
L-PAM i.p. For experimental studies, i.p. or i.v. inocula of
105 cells into CD2F1 mice were used. The L1210 subline
resistant to cDDP, L1210/cDDP (originally obtained from
NCI, NIH, Bethesda, MD, USA) was maintained by weekly
i.p. passages of 106 cells/mouse in DBA/2 mice, treated
weekly with 5mgkg-' of cDDP; in experiments, 105 cells/
mouse were transplanted i.v. in CD2F1 mice.
Solid tumours The Lewis lung carcinoma 3LL (105 cells/
mouse) and the M5076 murine reticulosarcoma (5 x 105 cells/
mouse) (obtained from the DCT Tumor Repository, NCI,
Frederick, MD, USA), were tranplanted i.m. in C57B1/6
mice to evaluate the activity on primary tumour. The murine
mammary ca. (MTV) (20 x 106 cells/mouse) from a third
generation spontaneous tumour was inoculated s.c. in C3H/
He females (Di Marco et al., 1972).
The murine Colon 38 tumour was transplanted s.c. in
C57B1/6 mice using 15-20 mg of tumour brei. MX1 human
mammary carcinoma and CX1 human colon carcinoma
(NCI, NIH, Bethesda, MD, USA), N592 human small cell
lung carcinoma and A549 lung adenocarcinoma (ATCC
catalogue), LoVo and LoVo/DX colon carcinoma (Grandi et
al., 1986) were transplanted s.c. in athymic mice using
15-20 mg of tumour brei.
Drug administration
All drug solutions were prepared immediately before use.
Treatment was administered i.p., i.v. or orally (by stomach
tube) in a volume of 10 ml kg-' of body weight. Treatment
schedules are reported in the Results.
Evaluation ofanti-tumour activity and toxicity
In experiments in leukaemia models, drug activity was deter-
mined by comparing the median survival time (MST) of the
treated group with that of the control group, and results are
expressed as %T/C, where:
%T/C= MST of treated group x 100 MST of control group
In experiments with solid tumours, primary tumour growth
was assessed by caliper measurement, and tumour weight was
estimated according to Geran et al. (1972). The anti-tumour
effect was determined by change of tumour weights of the
treated group and that of the control group on a given day.
The percentage of tumour growth inhibition (%TI) was
calculated 1 week after the last treatment according to the
equation:
100_median tumour weight of treated group x 100 median tumour weight of control group
The number of long-term survivors refers to mice surviving
at the end of the experiment: >60 days from tumour im-
plant for leukaemias, > 120 days from tumour implant for
murine solid tumours. For human solid tumours, the
tumour-free mice 60 days after tumour implant are con-
sidered cured mice.
Toxicity was evaluated on the basis of the gross autopsy
findings and the weight loss. In the experiments on solid
tumours, tumour-bearing mice were observed for 4 months
after the beginning of treatment for evaluation of lethality.
Mice are considered to have died of toxicity when death
occurred before the controls, or when significant body weight
loss and/or spleen and liver size reductions were observed.
Results
The structure of FCE 23762 is reported in Figure 1. The
lipophilicity of the compound was evaluated by means of a
direct RP-HPLC (reverse phase-high performance liquid
chromatography) method (Facchetti et al., 1991) and lipo-
philicity is expressed as the capacity factor evaluated at 0%
of the organic phase (log K.) which is the retention index. At
pH 7, FCE 23762 (log KO = 2.768) is more lipophilic than
DX (log K,o = 0.795).
Antileukaemic activity
Results obtained by comparing the anti-tumour activity of
FCE 23762 and DX on P388 and P388/DX leukaemias are
reported in Table I.
Against i.p. implanted P388 leukaemia, FCE 23762 and
DX presented equivalent efficacy with a %T/C value of 243
and 290 at the optimal dose of 0.15 mg kg-' and 15 mg kg-l
respectively. Against the two ascitic DX-resistant P388 sub-
lines, the compound maintained activity with a %T/C value
of 155 and 165, whereas DX was completely ineffective.
Equivalent results were observed after i.v. and oral treatment
against disseminated P388 and P388/DX leukaemias; FCE
23762 was in fact able to increase the survival time in all
three models at the optimal dose of 0.092-0.11 mg kg-' and
0.15mgkg-' after i.v. and oral administration respectively.
In the evaluation of the anti-tumour activity by the oral
route, the comparison with DX is not reported. DX is in fact
inactive by this route (Barbieri et al., 1987).
Table II demonstrates that the efficacy observed against
i.p. or i.v. injected P388/DX leukaemia is maintained when
cells are implanted subcutaneously. In fact tumour inhibition
values of 90% and 85% were observed with the two tested
treatment schedules; this activity was also reflected by a
remarkable increase in the survival time. The two schedules
utilised appear to be equally effective. This was also observed
against disseminated P388/DX leukaemia where different
repeated treatment schedules were assayed, obtaining anti-
tumour activity equivalent to that observed after single
administration (data not shown).
Because of the high lipophilicity of the compound, we
investigated the activity of FCE 23762 against intracranially
implanted P388 leukaemia (Table III). In this particular
model, we utilised BCNU as positive control. The drug given
as single i.v. treatment was ineffective in increasing the sur-
vival time of mice; this result representing a possible indica-
tion that the compound does not cross the blood-brain
barrier.
The anti-tumour activity of FCE 23762 was also explored
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Table I Activity of FCE 23762 and DX against P388 sensitive and resistant to DX (P388/DX) murine
leukaemias
Tumour Treatment Dose P388 P388/DX J. P388/DX S.
Compound sited schedule (mgkg-') %T/C' TOXC %TICb TOXC %T/Cb TOXy
FCE 23762 i.p. i.p. d, 0.15 243 0/30 155 0/10 165 1/10
0.2 148 22/40 81 10/10 - -
DX i.p. i.p. d, 10 240 0/50 100 0/10 110 0/10
15 290 1/10 104 2/10 - -
FCE 23762 i.v. i.v. d, 0.092 250 0/10 192 0/39 153 0/18
0.11 88 10/10 208 4/49 130 15/18
i.v. os. d1 0.12 160 0/10 167 0/10 n.t.
0.15 200 0/10 175 1/20 n.t.
DX i.v. i.v. d, 13 175 1/10 95 2/20 105 0/18
16.9 188 4/10 95 3/30 99 6/18
n.t. = not tested. aTumour cells wereinoculated at day 0. bMedian survival time oftreatedmice/median survival
time ofcontrols x 100. cNumber of toxic deaths/number of mice, evaluated in tumour bearing mice.
Table II Activity of FCE 23762 and DX against subcutaneous
P388/DX Johnson murine leukaemia with different treatment
schedulesa
Route and treatment Dose
Compound schedule (mgkg-') %T/C6 %TT TOXd
FCE 23672 i.v. d1,8 0.031 111 23 0/10
0.047 118 45 0/10
0.07 170 90 0/9
DX i.v. d,,8 6 103 32 1/9
7.5 107 38 1/10
9 96 50 1/10
FCE 23762 i.v. dl,4,7,11 0.025 111 31 0/9
0.0325 141 29 0/10
0.05 196 85 0/10
0.075 96 n.d. 10/10
DX i.v. dl,4,7,11 3 103 16 0/9
4.5 111 59 1/8
6.75 107 61 1/8
a106cells/mouseimplanted s.c. in avolumeof0.5 mlatday0. bMedian
survival time of treated mice/median survival time of controls x 100.
cThe percentage oftumour growth inhibition was calculated in respect
tocontrols onday 11 aftertumourcelltransplantation (day0). dNumber
of toxic deaths/number ofmice, evaluated in tumour bearing mice.
Table III Activity of FCE 23762 and BCNU against intracranially
transplanted P388 leukaemiaa
Route and treatment Dose
Compound schedule (mg kg-') %T/Cb TOX
FCE 23762 i.v. d, 0.09 104 0/10
i.v. d, 0.11 112 0/10
i.v. d, 0.13 60 9/10
BCNU i.v. d, 10 180 0/10
i.p. d, 20 >480 0/10
i.p. d, 30 >480 0/10
a104 cells were implanted intracranially in a volume of0.02 ml at day
0. bMedian survival time of treated mice/median survival time of
controls x 100. cNumber oftoxic deaths/number ofmice, evaluated in
tumour bearing mice.
resistant to L-PAM (L1210/L-PAM) and cDDP (L1210/
cDDP) (Table IV). The compound was equally effective on
the sensitive and cDDP resistant leukaemias, as indicated by
the %T/C values of 169 and 164 after i.v. administration,
and 150 and 171 after oral administration; on the subline
resistant to L-PAM, the compound was also effective,
although at a lesser degree. The increase in survival time was
in fact of 21% (i.v. route) and of 40% (oral route).
Anti-tumour activity against solid murine models
A parallel evaluation of the activity of FCE 23762 and DX
was carried out on four solid murine tumour models. In all
models only the results with DX at the optimal dose are
reported.
Table V presents results obtained in two i.m. implanted
solid tumours. On Lewis lung carcinoma, FCE 23762 was
Table IV Activity of FCE 23762 on disseminated L1210, L1210/L-
PAM and L1210/cDDP leukaemias
Route and treatment Dose
Cell linea schedule (mgkg-') %T/C TOX
L1210 i.v. d, 0.092 146 0/20
0.11 169 0/18
os. d, 0.16 150 0/10
0.2 183 3/20
L1210/L-PAM i.v. d, 0.092 121 0/20
0.11 134 4/29
os. d, 0.2 140 0/20
0.3 148 7/20
L1210/cDDP i.v. di 0.092 164 0/10
0.11 114 8/20
os. di 0.2 171 0/10
0.3 100 8/10
aj0S cells were transplanted i.v. at day 0. bMedian survival time of
treated mice/median survival time ofcontrols x 100. CNumber oftoxic
deaths/number ofmice, evaluated in tumour bearing mice.
marginally effective in reducing tumour growth, as indicated
by %TI values of 36 obtained after i.v. administration of
0.1mgkg-' at days 1, 8, 15 and %TI of 40 after oral
administration with 0.13 mgkg' every 4 days. On M5076
reticulosarcoma, the compound was as active as DX, both in
inhibiting tumour growth (%TI 94) and in increasing the
survival time (%T/C 159).
Results obtained testing the activity of FCE 23762 on s.c.
implanted MTV mammary carcinoma and Colon 38 models
are reported in Table VI.
The compound was as active as DX against MTV carcin-
oma, as indicated by %TI values of 75 and 90 after i.v. and
oral treatment, this last treatment also being effective in
increasing the survival time (%T/C 150). Conversely, the
compound differs from DX in being inactive against the
colon 38 model.
Anti-tumour activity against human models
The activity of FCE 23762 in comparison with DX on a
panel of s.c. implanted human tumour models, is reported in
Tables VII and VIII. Table VII reports results obtained on a
human mammary carcinoma, MX-1 and two lung tumours,
N592 (small cell carcinoma) and A549 (adenocarcinoma).
The compound shows better efficacy than DX on MX1
mammary carcinoma, both after i.v. and oral administra-
tions, giving a 99% reduction of tumour growth (%TI) with
90% of cured mice. Better efficacy in comparison with DX
was also observed on N592 small cell lung carcinoma (%TI
89 vs 55), whereas both compounds were marginally effective
on A549 adenocarcinoma (%TI 29 and 31).
Table VIII presents the results obtained testing the activity
of FCE 23762 on two human colon models, CX-l and LoVo,
and the derived DX-resistant tumour, LoVo/DX. In the
experimental conditions investigated, no anti-tumour activity706 V. RIPAMONTI et al.
Table V Activity of FCE 23762 and DX on 3LL and M5076 murine solid tumour
models
Tumour and site Route and treatment Dose
ofimplant2 Compound schedule (mgkg-') %TIC" %TI TOX"
3LL i.m. FCE 23762 i.v. d1,8,15 0.1 133 36 0/10
0.13 80 n.d. 10/10
os. d4,8,12,16 0.13 113 40 0/10
0.16 117 60 4/10
DX i.v. dl,8,15 7.5 172 100 0/20
M5076 i.m. FCE 23762 i.v. dl,8,15 0.075 159 94 0/10
0.1 66 n.d. 10/10
DX i.v. dl,8,15 6 143 93 0/10
aTumour cells were inoculated at day 0. bMedian survival time of treated mice/median
survival time ofcontrols x 100. cThe percentage oftumour growth inhibition was calculated
in respect to controls 1 week after tumour cell transplantation (day 0). dNumber of toxic
deaths/number ofmice, evaluated in tumour bearing mice.
Table VI Activity ofFCE 23762 and DX on MTV and on Colon 38 murine solid tumour
models
Tumour and site Route and treatment Dose
ofimplant' Compound schedule (mgkg-') %TIC' %TIC TOXd
MTV s.c. FCE 23762 i.v.- q7d x 4 0.05 138 75 0/10
0.075 121 90 4/6
os.- q7dx4 0.12 150 90 0/9
0.155 65 n.d. 9/9
DX i.v.- q7d x 4 6 124 91 1/9
Colon 38 s.c. FCE 23762 i.v.- q7d x 4 0.05 90 7 0/9
0.075 51 32 3/9
os.- q7d x 4 0.12 86 20 0/9
0.15 77 35 3/9
DX i.v.- q7d x 4 6 93 82 0/9
aTumour cells were inoculated at day 0. Treatment was started when the tumour was
palpable. bMedian survival time oftreated mice/median survival time ofcontrols x 100.cThe
percentage of tumour growth inhibition was calculated in respect to controls 1 week after
tumour cell transplantation (day 0). dNumber oftoxic deaths/number ofmice, evaluated in
tumour bearing mice.
Table VII Antineoplastic activity of FCE 23762 on human solid tumours
xenografted in athymic mice
Route and treatment Optimal dose' %Cured
Tumoura Compound schedule (mgkg-') %TIC mice"
MX1 FCE 23762 i.v.- q7d x 3 0.07 99 19/20
os.-q7d x 3 0.13 99 5/7
DX i.v.- q7d x 3 6.6 72 0/7
N592 FCE 23762 i.v.- q7d x 3 0.085 89 0/8
DX i.v.- q7d x 3 6 55 0/8
A549 FCE 23762 i.v.- q4d x 4 0.045 29 0/7
DX i.v.- q4dx4 4 31 0/7
aTumour fragments (3mm3) were implanted s.c. by trocar on athymic (nu/nu)
mice on day 0. Treatment was started when the tumour was palpable. bOptimal
dose is defined as the dosage giving the best %TI with toxicity < 10%. cThe
percentageoftumourgrowth inhibition wasdeterminedaweekaftertheend ofthe
treatment. dAll mice which are tumour free 60 days after tumour implant.
Table VIII Antineoplastic activity of FCE 23762 and DX on human colon
adenocarcinomas xenografted in athymic mice
Route and treatment Optimal dose"
Tumour" Compound schedule (mgkg-') %TO
CX-1 FCE 23762 i.v.- q4d x 4 0.045 9
DX i.v.- q4d x 4 5.2 34
LoVo FCE 23762 i.v.- q7d x 3 0.046 33
i.v.- q4d x 4 0.045 43
os.- q4d x 6 0.08 52
DX i.v.- q4d x 4 4 83
LoVo/DX FCE 23762 i.v.- q4d x 4 0.06 37
os.- q4d x 6 0.1 37
DX i.v.- q4d x 4 5.2 12
aTumour fragments (3mm3) were implanted s.c. by trocar on athymic (nu/nu)
mice onday 0. Treatment was started when the tumour was palpable. Thenumber
ofmice for group range from 6 to 9. bOptimal dose is defined as the dosage giving
the best %TI with toxicity <10%. 'The percentage oftumour growth inhibition
was determined 1 week after the end of the treatment.ANTI-TUMOUR ACTIVITY OF FCE 23762 707
was observed on the CX-1 model, after treatment with FCE
23762 and only marginal activity after treatment with DX.
Comparable although borderline values in terms of %TI
were observed on LoVo and LoVo/DX tumours when the
compound was administered i.v. and orally with different
treatment schedules; in these models DX was active only on
the LoVo model (%TI 83) and inactive on LoVo/DX model
(%TI 12).
In all tested models, the major toxic effects observed after
FCE 23762 treatment were body weight loss and organs
reduction, in particular spleen and liver, these being the
classic toxic effects of anthracyclines.
Discussion
This report presents the pattern of anti-tumour activity of
FCE 23762, a novel derivative of DX bearing the methoxy-
morpholinyl group at position 3' of the sugar moiety.
The high lipophilicity of the molecule confers to FCE
23762 the characteristic of also being effective after oral
administration; with this route, the optimal doses were
between 1.5 and 2-fold higher than after i.v. administration.
In contrast with previous observations on another morph-
olino derivative MX-2 (Izumoto et al., 1990) which is also
highly lipophilic, FCE 23762 is inactive on intracranially
implanted P388 leukaemia, this finding pointing to the possi-
bility that the compound does not pass the blood-brain
barrier.
Lipophilicity presumably also plays a role in the observed
efficacy of FCE 23762 on DX-resistant cells in vitro and in
vivo. In fact, anthracyclines more lipophilic than DX or
DNR are generally more active on MDR cells (Facchetti et
al., 1991) and are able to reach higher intracellular concent-
rations. Among these, FCE 23762 was shown to accumulate
at high levels in all tested tumour cell lines, both sensitive
and expressing the MDR phenotype (Grandi et al., 1990b).
Another factor to be taken into consideration is, however,
the possible lower affinity to p170 of this class ofcompounds.
The results presented in this report indicate a consistent
efficacy of FCE 23762 on DX-resistant P388 leukaemia cells
implanted at different sites and with different routes of
administration. This lack of cross-resistance to DX is also
confirmed on two solid human tumour models, LoVo and
LoVo/DX, where treatment with the compound was similarly
effective, although at borderline levels of efficacy. Similar
results were obtained on a murine fibrosarcoma model UV-
2337 sensitive and resistant to DX (Giavazzi, in preparation).
FCE 23762 was also effective on L1210 murine leukaemia
and on two L1210 sublines resistant to L-PAM and cDDP,
in the latter showing an activity equivalent to that seen on
the wild-type line.
On solid tumours models FCE 23762 was able to inhibit
tumour growth on different systems, with remarkable efficacy
on MTV mammary carcinoma, M5076 murine reticulosar-
coma, N592 human small cell lung cancer and MX-1 human
mammary carcinoma. In this last model the drug was con-
sistently more effective than DX, with an elevated number of
mice surviving tumour-free after >60 days.
FCE 23762 differs from most anthracyclines in being acti-
vated to a highly potent metabolite(s) when injected in vivo.
This is suggested by the finding that FCE 23762 is only 3-4
fold more cytotoxic than DX in vitro, whereas it is >80 fold
more potent when administered to mice (Grandi et al.,
1990b). This contention is reinforced by the recent report of
Lau et al. (1991), describing FCE 23762 being metabolised in
vitro in the presence of human liver microsomes to a highly
cytotoxic metabolite(s) able to alkylate DNA. Notwithstand-
ing this possible alkylating activity, however, FCE 23762
maintains anti-tumour efficacy on L1210 leukaemias resistant
to cDDP and L-PAM. The structure of the metabolite(s) is
under active investigation.
The toxicity observed after treatment with FCE 23762 are
those typical of classic anthracyclines with a low therapeutic
index at the treatment schedules employed. We are now
setting up a sensitive enough analytical method to evaluate
the plasma AUC (area under curve) at the therapeutic and
toxic doses, with the objective of identifying the best treat-
ment schedules. However, because of its efficacy in vitro and
in vivo on MDR tumour cells and pattern of anti-tumour
activity in the tested models, as well as its unusual mode of
action, this compound is recommended for clinical testing.
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